Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
November 30, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly...